𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Catechol-O-methyltransferase val158met and cognitive function in Parkinson's disease

✍ Scribed by Jeroen Hoogland; Rob M.A. de Bie; Caroline H. Williams-Gray; Dino Muslimović; Ben Schmand; Bart Post

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
64 KB
Volume
25
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Cognitive dysfunction is one of the most incapacitating non‐motor symptoms of Parkinson's disease (PD). Some cognitive deficits are thought to be related to abnormal dopamine homeostasis. The latter is influenced by catechol‐O‐methyltransferase (COMT), an enzyme that degrades dopamine. Previous research suggests a relationship between the COMT val158met functional polymorphism (SNP) and measures of executive function. We evaluated this hypothesis in a cohort of PD patients with an extensive neuropsychological test battery. Cognitive assessment and COMT genotyping were performed in 153 early PD patients from outpatient clinics general hospitals in the Netherlands. Our results do not support a direct effect of COMT val158met genotype on performance on neuropsychological measures of attention and executive function, but they suggest that genotype may interact with dopaminergic medication use to influence cognitive ability. © 2010 Movement Disorder Society

📜 SIMILAR VOLUMES

Catechol-O-methyltransferase Val158Met a
Catechol-O-methyltransferase Val158Met and the risk of dyskinesias in Parkinson's disease
✍ Lonneke M.L. de Lau; Dagmar Verbaan; Johan Marinus; Peter Heutink; Jacobus J. va 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 1006 KB

## Abstract ## Background: The A‐allele of the catechol‐__O__‐methyltransferase (__COMT__) Val158Met polymorphism is associated with decreased enzymatic activity and higher dopamine availability. ## Methods: We studied 219 patients with PD who were free of dyskinesias at baseline and underwent t

Catechol-O-methyltransferase val108/158m
Catechol-O-methyltransferase val108/158met genotype and response to antipsychotic medication in schizophrenia
✍ Ari Illi; Olli Kampman; Kari Hänninen; Sami Anttila; Kari M. Mattila; Heikki Kat 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB

## Abstract Catechol‐O‐methyltransferase (COMT) gene has been investigated as a possible candidate gene in schizophrenia. The most studied polymorphism has been the functional val108/158met polymorphism of this COMT gene. There is also some evidence that this polymorphism could be related to drug r

Influence of the tyrosine hydroxylase va
Influence of the tyrosine hydroxylase val81met polymorphism and catechol-O-methyltransferase val158met polymorphism on the antidepressant effect of milnacipran
✍ Keizo Yoshida; Hisashi Higuchi; Hitoshi Takahashi; Mitsuhiro Kamata; Kazuhiro Sa 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 119 KB

## Abstract ## Objective Genetic polymorphisms of the noradrenergic pathway can be factors to predict the effect of antidepressants when their pharmacological mechanisms of action include the noradrenergic system. The purpose of the present study was to determine whether the tyrosine hydroxylase (

Planning ability in Parkinson's disease
Planning ability in Parkinson's disease is influenced by the COMT val158met polymorphism
✍ Thomas Foltynie; Terry E. Goldberg; Simon G.J. Lewis; Andrew D. Blackwell; Bhask 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

## Abstract Parkinson's disease (PD) patients show a range of executive deficits involving dopaminergic transmission in the prefrontal cortex. In this study, we have investigated the impact of catechol‐O‐methyl‐transferase (COMT) val^158^met polymorphisms on performance of the Tower of London (TOL)